1. NORDION
Corporate Presentation
March 7, 2014
www.nordion.com

2. Caution on Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of applicable securities laws, including under
applicable Canadian securities laws and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act
of 1995. These statements can be identified by expressions of belief, expectation or intention, as well as those statements that are
not historical fact. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”
and similar words and expressions are also intended to identify forward-looking statements. Forward-looking statements are
necessarily based on estimates and assumptions made by us in light of our experience and our perception of historical trends,
current conditions and expected future developments, as well as other factors that we believe are appropriate in the
circumstances, but which are inherently subject to significant business, political, economic and competitive uncertainties and
contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forwardlooking statements. Accordingly, this presentation is subject to the disclaimer and qualified by the assumptions, qualifications and
risk factors referred to in our 2013 Annual Information Form (AIF).
We caution readers not to place undue reliance on the Company’s forward-looking statements, as a number of factors could
cause our actual results, performance or achievements to differ materially from any forward-looking statements. We do not
assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to
time by us or on our behalf, except as required by applicable law.
2

3. About Nordion
Nordion is a health science company that
provides market-leading products used for
the prevention, diagnosis and treatment of
disease.
Delivering quality products to our global
customers for more than 60 years, our product
portfolio includes:
• Sterilization Technologies
• Medical Isotopes
3

4. A Global Company
F2013 REVENUES BY REGION - $232.8M*
64%
UNITED STATES
23%
5%
CANADA
ROW
8%
EUROPE
APPROXIMATELY
AROUND
SUPPLY OVER
ACROSS MORE THAN
400 EMPLOYEES
30 PRODUCTS
500 CUSTOMERS
40 COUNTRIES
4
*Revenues and regional breakdown include Targeted Therapies business, which was divested in July 2013 to BTG plc.

5. 2013 Financial Highlights
Revenue Trend (US$ Millions)
Sterilization Technologies
Medical Isotopes
Targeted Therapies*
300
250
42.6
48.5
36.3
101.0
100.3
108.7
95.4
96.1
2011
2012
2013
200
122.8
150
100
50
0
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
5

6. 2013 Financial Highlights
Segment Earnings Trend (US$ Millions)
Sterilization Technologies
Medical Isotopes
Targeted Therapies*
120
100
12.7
80
60
14.1
38.3
3.0
29.4
25.9
40
20
46.1
39.0
35.3
2012
2013
0
2011
Excludes corporate segmented loss
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
6

7. Q1 2014 Results
Sterilization Technologies
Medical Isotopes
Targeted Therapies
Segmented Revenue
Segmented Earnings*
(US$ millions)
(US$ millions)
80.0
35.0
70.0
30.0
60.0
50.0
25.0
12.0
51.7
20.0
25.1
40.0
15.0
30.0
25.2
10.0
20.0
1.4
6.9
10.0
19.2
16.4
5.0
7.1
3.5
0.0
0.0
2013
Q1
2014
2013
Q1
* Excludes corporate segment
2014
7

8. Q1 2014 Timeline
Nordion participates at the
2013 International Meeting on
Radiation Process in
Shanghai, China
Nordion publishes its fiscal
2013 Annual Report and
files associated disclosure
documents.
November
January
Q1 2014
Nordion posted its 2012
Annual Report on Toxic
Substance Reduction
December
Nordion signs customer
contracts to supply
strontium-82 and cobalt.
January
8

9. Leading Products in Global Markets
STERILIZATION
TECHNOLOGIES
MEDICAL
ISOTOPES
Maintain Sterilization business;
selectively invest in growth:
• Geographic expansion
• New applications
Optimize Medical Isotopes business
• Secure long-term supply
• Maintain customer relationships
POTENTIAL >
Approximately 40% of single-use medical
products worldwide are sterilized using
gamma sterilization technologies
Over 10,000 hospitals worldwide use
radioisotopes in medical procedures with
about 90% being for diagnosis.
ADVANTAGE >
• Global leader in cobalt-60
• Significant barriers to entry
• Solid cash flow and gross margins
• Recurring revenue base
• A global provider in
processing, packaging, & delivery
• Extensive regulatory expertise and
logistics & distribution network
PRIORITY >
9

10. Specialty Isotopes: Sterilization Technologies
•
Gamma sterilization is focused on
the prevention of disease
•
Co-60 is used to sterilize medical devices,
instruments and supplies and food
•
Customers of Co-60 include
contract sterilization service providers
and medical device and product manufacturers
•
The Nordion Gamma Centre of Excellence is a
world class applied research and specialty gamma
processing facility to promote and expand the use
of gamma globally
•
Nordion manufactures Co-60 irradiation sources,
and designs, constructs and maintains commercial
gamma sterilization systems
10

11. Sterilization Market Segmentation
MARKET MIX
80%
MEDICAL & SURGICAL
PRODUCTS
•
•
•
•
Syringes
Catheters
Drapes, gowns
Sutures, gloves
10%
•
•
•
•
Stents
Patches
Tissue
Regen medicine
10%
10%
•
•
•
•
Fruits & vegetables
Spices
Meat and poultry
Ready To Eat (RTE)
BIO-ACTIVE DEVICES
FOOD SAFETY
DRIVERS
+ Aging population
+ Min invasive surgery
+ Smaller devices
+ Material
+ Aging population
+ Enhance devices
+ Leverage drugs
+ Stem cell research
+ FDA labeling
+ USDA FEA
+ Food safety concerns
11

12. Specialty Isotopes: Medical Isotopes
•
Medical isotopes are used to prevent, diagnose
and treat disease
•
Main isotope supply sources
are nuclear reactors and cyclotrons
•
Primary product is Mo-99, which decays for use in
Technetium-99 (Tc-99m) generators, used in
imaging to diagnose heart disease and cancers
•
Other Key Reactor Isotopes:
–
–
Iodine-131 (I-131), used to treat hyperthyroidism, thyroid cancer and
non-Hodgkin’s lymphoma;
–
Iodine-125 (I-125), used to treat prostate cancer;
–
•
Xenon-133 (Xe-133), used in lung scans;
Yttrium-90 (Y-90), used to treat liver cancer.
Key Cyclotron Isotopes:
–
Iodine-123 (I-123), used to diagnose thyroid disease;
–
Strontium-82 (Sr-82), used to manufacture rubidium-82 generators,
which are used in imaging to diagnose heart disease
–
Thallium-201 (Tl-201), used to diagnose and assess risk of coronary
artery heart disease;
–
Palladium-103 (Pd-103), used to treat prostate cancer;
–
Indium-111 (In-111) and Gallium-67 (Ga-67) (both used to diagnose
infection and cancer) at our Vancouver facilities
12

13. Medical Isotopes (Mo-99) Supply Chain
NUCLEAR
REACTORS
RADIOPHARMACEUTICAL
MANUFACTURERS
RADIOPHARMACIES
AND HOSPITALS
PHYSICIANS
AND PATIENTS
Irradiation of
HEU targets to
produce crude
isotopes
•
•
MEDICAL ISOTOPE
PROCESSORS
Purification of
Mo-99 and
distribution to global
radiopharmaceutical
manufacturers
Tc-99m
Generator
manufacturing
and distribution to
radiopharmacies
Unit dose
compounding and
distribution to
hospital/departments
Critical physiological
diagnosis enabling
informed therapeutic
decisions
Established, reliable facilities providing high-quality isotopes to global customers
Specialty skills in operations, regulatory affairs and global logistics
13

14. Nordion Environmental, Health,
and Safety (EH&S) Program
• Creating a workplace that enriches
the health and well-being of Nordion
employees
• Demonstrating Environmental, Health,
and Safety (EH&S) regulatory excellence
• Improving EH&S performance –
continually
• Managing EH&S with excellence
Recipient of Canada’s Safest
Employers - Gold level award
October, 2013
14

15. Nordion Environmental, Health,
and Safety (EH&S) Program
•
Implementing measures in the design and operation of all of
our facilities to keep radiation dose received by workers and
the public ALARA (as low as reasonably achievable)
•
Implementing an ISO 14001-based environmental
management (EMS) system at our Ottawa site
•
Establishing EH&S objectives and targets annually
to continually improve our performance
•
Maintaining - and building on - a comprehensive training
program for employees and contractors
•
Engraining EH&S excellence into the Nordion culture
•
Investing in a world class approach to EH&S
ISO 14001: 2004 certified
Recipient of the Government of Canada 2007 ENERGY STAR ® Market Transformation Award
Practitioner of LeanSigma, a methodology used to continually improve processes
Recipient of an unprecedented ten-year license renewal from the Canadian Nuclear Safety Commission (CNSC)
15

16. In the Community
Ride the Rideau
Sponsor of Ride the Rideau since its inauguration in 2010, Nordion has helped to raise
over $6.4 million for cancer research at The Ottawa Hospital Research Institute.
Other Programs:
• Employee Giving Program - Nordion
makes donations to not-for-profit
organizations nominated by employees
• Proud sponsor of the Gala for Research,
an annual black-tie event to support
the Ottawa Hospital Research Institute,
the research arm of The Ottawa Hospital
16

17. Business Outlook
The talented, dedicated and
resilient people that make
up Nordion share a single
purpose:
• Maintain a global leadership
position in our key markets
• Build value for shareholders
through the execution of our
strategic priorities
• Be a trusted, world-class provider
of healthcare products to our
customers
17

18. Find out more at
www.nordion.com
Follow us at
http://twitter.com/NordionInc
www.nordion.com